The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils

Understanding how small molecules bind to pathological aggregates is of importance for therapeutic and diagnostic development in diseases such as Parkinson’s Disease. Here, the authors reveal a binding site of anle138b to lipid-induced α-synuclein fibrils.

Bibliographic Details
Main Authors: Leif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, Benedikt Frieg, Christian Dienemann, Andrei Leonov, Evgeny Nimerovsky, Vrinda Sant, Sergey Ryazanov, Armin Giese, Gunnar F. Schröder, Stefan Becker, Bert L. de Groot, Christian Griesinger, Loren B. Andreas
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-32797-w

Internet

https://doi.org/10.1038/s41467-022-32797-w

Similar Items